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1	Introduction
The	Safety	Qualification	of	Excipients	was	one	of	the	sessions	organized	at	a	public	workshop	entitled	“Challenges	and	strategies	to	facilitate	formulation	development	of	pediatric	drug	products”	held	June	8–9,	2016	at	the
College	 Park	Marriott	 Hotel	 and	 Conference	 Center	 in	 Hyattsville,	MD.	 The	 session	 was	 designed	 to	 bring	 together	 various	 stakeholders	 (eg,	 EU-	 and	 US-based	 formulators,	 regulators,	 clinicians,	 and	 toxicologists)	 to	 discuss
approaches	to	the	safety	assessment	of	excipients	and	to	identify	gaps	and	challenges	in	current	paradigms	to	assess	excipient	safety	and	evaluate	the	potential	risk	thereof	in	pediatric	formulations.	An	ultimate	goal	was	to	develop
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Abstract
A	public	workshop	entitled	“Challenges	and	strategies	 to	 facilitate	 formulation	development	of	pediatric	drug	products”	 focused	on	current	 status	and	gaps	as	well	as	 recommendations	 for	 risk-based	strategies	 to
support	 the	 development	 of	 pediatric	 age-appropriate	 drug	 products.	 Representatives	 from	 industry,	 academia,	 and	 regulatory	 agencies	 discussed	 the	 issues	within	 plenary,	 panel,	 and	 case-study	 breakout	 sessions.	 By
enabling	practical	and	meaningful	discussion	between	scientists	representing	the	diversity	of	involved	disciplines	(formulators,	nonclinical	scientists,	clinicians,	and	regulators)	and	geographies	(eg,	US,	EU),	the	Excipients
Safety	workshop	session	was	successful	 in	providing	specific	and	key	recommendations	for	defining	paths	forward.	Leveraging	orthogonal	sources	of	data	(eg.	food	industry,	agro	science),	collaborative	data	sharing,	and
increased	awareness	of	 the	existing	 sources	 such	as	 the	Safety	 and	Toxicity	 of	Excipients	 for	Paediatrics	 (STEP)	database	will	 be	 important	 to	 address	 the	gap	 in	 excipients	 knowledge	needed	 for	 risk	assessment.	The
importance	of	defining	risk-based	approaches	to	safety	assessments	for	excipients	vital	to	pediatric	formulations	was	emphasized,	as	was	the	need	for	meaningful	stakeholder	(eg,	patient,	caregiver)	engagement.
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recommendations	for	a	risk	to	benefit	–	based	framework	to	qualify	excipients	for	pediatric	use.	This	report	summarizes	the	plenary	presentations	and	the	working	group	discussions	on	the	current	perspectives	on	approaches	to	safety
assessments	of	excipients	intended	for	pediatric	use.	It	includes	a	number	of	considerations	and	recommendations	for	future	best	practices	put	forward	by	the	participants	and	experts	in	the	workshop.
1.1	Overview	of	challenges	and	opportunities	in	safety	assessment	of	excipients	in	pediatric	drug	products
Pediatric	drug	development	has	been	stimulated	by	recent	legislation	(US	and	EU	regulations),	resulting	in	significant	efforts	to	develop	age-appropriate	formulations	acceptable	for	use	in	pediatric	patients.	Dr.	Buckley	opened
the	session	with	an	overview	of	the	issues	and	gaps	in	current	safety	assessment	paradigms	for	excipients	in	pediatric	patient	populations	(Fig.	1).	The	pediatric	population,	which	spans	from	neonates	to	adolescents	(0–17	years),	is
quite	 heterogeneous	with	 regard	 to	 a	multitude	 of	 factors	 including	 difference	 in	 swallowing	 abilities,	 taste	 preferences,	 and	 dosage	 requirements	 depending	 on	 the	 age	 and	 the	 clinical	 state	 of	 the	 patient.	 This	 heterogeneity
represents	a	significant	challenge	for	drug	development	teams	for	designing	safe	and	age-appropriate	formulations	for	pediatric	products.	Considerable	cross-functional	collaboration	involving	chemists/formulators,	drug	disposition
scientists,	clinicians,	and	toxicologists	is	required	as	the	development	team	considers	total	doses,	(maximum)	concentrations	and	amount	of	excipients,	dosing	regimen,	duration	of	treatment,	route	of	administration,	as	well	as	the
indication	 and	 the	 (minimum)	age	groups	 (Schmitt,	2015)	 during	 safety	 assessments	 of	 excipients.	 Further,	 knowledge	 of	 these	 factors,	 including	 the	 intended	patient	 population,	 is	 usually	 in	 flux	 or	 uncertain	 over	 the	 course	 of
development	of	a	drug.
One	of	the	challenges	and	key	elements	of	pediatric	formulation	development	is	the	screening	and	careful	selection	of	excipients	(EMA,	2013),	as	certain	excipients	safely	used	in	adult	formulations	(eg,	benzyl	alcohol,	ethanol,
propylene	glycol,	parabens)	are	associated	with	elevated	toxicological	risks	and	safety	issues	when	used	in	children,	even	at	age-adapted	lower	concentrations	(Fabiano	et	al.,	2011).	Hence,	a	comprehensive	safety	assessment	of	the
excipients	in	a	pediatric	formulation	is	essential.	A	compilation	of	all	nonclinical	and	human	safety	data	should	be	assessed	for	inclusion	of	an	excipient,	and	that	data	placed	into	context	with	the	risk	and	the	anticipated	health	benefit
of	the	formulation	to	the	patient.	For	a	well-established	excipient	commonly	used	in	foods	or	other	therapeutic	formulations,	known	use	experience	should	be	leveraged.	While	additional	nonclinical	studies	may	be	conducted	to	support
safety	of	 the	excipient,	such	 information	 is	 typically	restricted	 to	regulatory	discussions	supporting	 the	 formulation	development	of	a	particular	product	and	 is	not	publicly	available.	Thus,	 the	safety	qualification	of	excipients	 for
pediatric	use	is	confounded	by	limited	availability	of	and	access	to	safety	data	(especially	for	pediatric	use)	as	well	as	uncertainties	in	extrapolations	of	exposure	and	effect	between	adults	and	children	or	between	nonclinical	species
and	humans.	Although	regulatory	guidance	documents	provide	some	direction	regarding	excipient	 safety	assessment	 (US	FDA,	2005;	EMA,	2013),	 there	 is	 a	 lack	of	 standardization	with	 regard	 to	what	 is	 adequate	or	necessary	 to
sufficiently	characterize	the	risk-benefit	profile	 for	excipient	use	 in	various	pediatric	populations	and	disease	states.	Throughout	the	session,	participants	highlighted	a	number	of	challenges	and	opportunities	 for	realizing	the	 full
potential	of	a	better-integrated	application	of	risk	assessment	framework	on	safety	assessment	of	excipients	and	stakeholder	decision-making.
1.2	The	need	for	a	risk-based	assessment	framework
In	the	plenary	presentation,	Dr	Turner	presented	the	current	clinical	and	patient	perspectives	regarding	the	use	of	excipients	for	neonatal	formulations.	Assessments	of	excipient	exposure	are	especially	sensitive	in	the	neonatal
situation	in	that	exposure	always	occurs	in	a	clinical	context	that	includes	long-term	concerns	about	development	as	well	as	treatment	of	acute	illnesses.	Dr.	Turner	emphasized	the	importance	of	considering	the	benefits	and	potential
harms	of	excipients	(in	addition	to	those	of	the	active	pharmaceutical	ingredient)	in	the	context	of	the	seriousness	of	the	disease	state	and	other	conditions	not	related	to	the	indication	(eg,	complications	of	prematurity).	While	some
notable	cases	of	severe	excipient	toxicity	have	been	obvious	against	background	morbidities,	eg,	Vitamin	E,	this	is	the	exception	rather	than	the	rule	(Arrowsmith	et	al.,	1989).
Fig.	1	Gaps	in	current	safety	assessment	paradigms	for	excipients	in	pediatric	patient	populations.
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The	clinical	example	of	inotrope	use	to	treat	hemodynamic	insufficiency	during	the	72	hours	after	birth	before	27	weeks	gestational	age	provides	a	good	example	of	the	need	to	consider	the	balance	of	risk	and	benefit.	The
seriousness	of	the	disease	state	is	evident	in	the	associated	mortality	(30%–50%)	and	morbidity	(brain	injury	leading	to	neurodisability	in	60%–80%	of	survivors).	In	this	case,	excipients	such	as	sodium	metabisulphite	are	necessarily	a
part	of	the	inotrope	formulation	to	improve	brain	perfusion.	As	some,	but	not	all,	adverse	events	associated	with	the	active	ingredient	are	accepted,	potential	harms	arising	from	excipients	should	be	similarly	accepted	if	those	harms
are	limited	and	do	not	make	a	material	difference	to	the	overall	benefit-risk	assessment.	One	must	consider	how	the	risk	of	excipient	compares	to	the	risk	of	the	condition.	While	it	is	difficult	to	attribute	injury	to	individual	causes	(such
as	drugs)	in	clinical	practice,	such	understanding	may	be	possible	at	population	level	under	good	circumstances	(eg,	following	a	randomized	controlled	trial).
When	determining	whether	an	excipient	is	safe	to	use	in	a	pediatric	formulation,	“Yes”	or	“No”	is	not	always	a	helpful	answer.	There	is	a	need	to	set	limits	on	excipient	exposure	that	are	related	to	the	context-of-use,	instead	of
simply	 allowing	 or	 banning	 excipient	 use.	 Assessing	 the	 risks	 arising	 from	 an	 excipient	 requires	 an	 understanding	 of	 relationships	 between	 administered	 dose	 and	 exposure	 (pharmacokinetic,	 PK)	 and	 exposure	 and	 response
(pharmacodynamic,	PD).	Thanks	to	recent	technical	advances	which	have	enabled	quantification	of	exposure	in	neonates,	dose-exposure	relationships	can	be	examined	(Mulla,	2015;	Pandya	et	al.,	2016).	In	cases	where	the	exposure-
response	relationship	currently	cannot	be	assessed	clinically,	PKPD	models	can	be	set	up	using	extrapolations	from	other	contexts	(animal	or	laboratory	models).	In	the	clinical	setting,	advice	is	also	needed	about	what	to	do	if	there	is	a
problem	that	may	be	attributed	to	excipients.
1.3	A	range	of	perspectives	regarding	the	safety	assessment	of	excipients
In	the	subsequent	Panel	Discussion,	perspectives	of	various	Panel	members	(authors	herein)	regarding	their	experiences,	expectations,	perceived	gaps	in	knowledge	and	process,	as	well	as	possible	risk-based	approaches	were
shared.	Key	observations	and	suggestions	from	the	panel	members	follow:
• The	group	noted	 the	 importance	of	 leveraging	existing	data	 collected	at	 the	different	 stages	 of	 safety	 assessment	 of	 excipients	 and	 the	need	 to	 create	 a	mechanism	 for	more	 seamless	 exchange	of	 data.	 The	 first	 step	 in	 safety	 assessment	 of	 excipients	 involves
comprehensive	and	critical	review	of	all	existing	data	to	acquire	a	depth	of	understanding	and	breadth	of	knowledge	beyond	that	of	a	single	stakeholder	(i.e.,	excipient	maker	or	formulator	alone).	Before	choosing	an	excipient,	literature	and	databases	such	as	the	STEP
database	(Salunke	et	al.,	2012,	2013;	Salunke	and	Tuleu,	2015)	should	be	searched	to	determine	1	if	safety	has	been	established	and	in	what	context,	2	what	gaps	exist	in	the	data,	and	3	the	necessity	of	any	additional	studies	to	assess	safety	of	the	excipient.	However,
the	 information	 is	currently	scattered	amongst	numerous	sources	making	 it	difficult	 for	 the	users	 to	systematically	review	the	existing	 information.	While	sharing	of	nonclinical	data	and	the	development	of	surveillance	tools	 to	monitor	post	marketing	safety	will
certainly	help	to	provide	further	data	to	support	novel	excipient	use,	safety	monitoring	is	complicated	by	the	other	components	of	the	products	and	therefore,	the	safety	signal	is	confounded.
• Toxicology	studies	in	juvenile	animals	may	be	necessary	if	the	use	of	an	excipient	in	a	pediatric	medicine	cannot	be	justified	based	on	existing	information	sources	(EMA,	2013a;	US	FDA,	2005;	US	FDA,	2016);	however,	the	standardized	conduct	of	juvenile	toxicology
studies	in	a	routine	“box-ticking”	manner	was	not	considered	appropriate.	Safety	assessment	should	primarily	focus	on	potential	effects	on	growth	and	development,	if	not	previously	characterized	(US	FDA,	2016).	When	a	cause	for	concern	is	identified,	the	juvenile
animal	toxicology	study	can	be	designed	to	assess	the	safety	of	both	the	excipient	and	the	active	moiety	(and,	if	warranted,	potential	interactions	thereof)	(Schmitt,	2015;	US	FDA,	2005;	US	FDA,	2016).	Finally,	both	the	rationale	for	conducting	a	juvenile	animal	study
and	the	design	of	the	study	should	be	influenced	by	its	relevance	and	ability	to	inform	clinical	safety	data.
• In	addition	to	nonclinical	safety	data,	existing	human	data	can	often	be	employed	to	justify	expanded	use	of	an	excipient.	Therefore,	it	is	important	that	sponsors	provide	regulatory	agencies	with	all	available	data	detailing	human	exposure	including,	for	example,	data
from	foods.	When	appropriate	this	prior	human	exposure	information	can	be	used	to	justify	use	of	an	excipient	and	minimize	the	need	to	evaluate	a	full	battery	of	toxicology	studies.
• Neonates	may	be	uniquely	vulnerable	to	adverse	events	related	to	excipients,	due	to	immature	absorption,	distribution,	metabolism,	and	elimination	pathways,	polypharmacy,	and	serious	illness.	Off-label	use	of	drugs	formulated	for	older	populations	remains	prevalent
(Hsieh	et	al.,	2014),	as	clinical	studies	that	meet	regulatory	approval	standards	are	historically	scarce.
• The	case	study	of	propylene	glycol	presented	by	Dr.	Carleer	highlighted	the	need	for	special	regulatory	and	safety	considerations	for	different	use	patterns	and	pediatric	patient	populations	(EMA,	2005;	EMA,	2013b).	Short-	to	medium-	term	treatment	of	pediatric
patients	(term	neonates	to	adolescent)	with	a	propylene	glycol-containing	solution	for	intravenous	infusion	have	been	considered	clinically	justified	when	urgent	treatment	was	needed	or	when	other	routes	of	administration	were	not	possible.	However,	safety	concerns
related	to	limited	metabolic	and	renal	clearance	in	neonates	and	young	children	have	driven	the	requirement	for	monitoring	the	potential	toxicity	of	propylene	glycol	in	pediatric	studies,	particularly	in	term	and	preterm	neonatal	patients	(EMA,	2005).	In	addition,	the
importance	of	potential	interactions	with	the	active	moiety	or	other	excipients	which	may	compete	for	the	same	clearance	pathway	(eg,	alcohol	dehydrogenase)	was	emphasized.	(Also	see	Kaletra	US	FDA	label,	Section	5.2,	 (The	US	FFDA	Kaletra	label	should	have	the	(US
FDA	2016)	reference	noted	here.)“Toxicity	in	Preterm	Neonates,”	which	explains	that	the	ethanol	(42.4%	v/v)	and	propylene	glycol	(15.3%	w/v)	excipients	in	the	solution	may	increase	risk	of	cardiac	toxicity,	lactic	acidosis,	renal	failure,	CNS	depression,	and	respiratory
complications	leading	to	death.	These	toxicities	were	reported	with	neonatal	administration	of	Kaletra,	primarily	in	preterm	neonates.)
• Safety	assessment	should	use	a	risk-benefit	approach	as	opposed	to	one	where	safety	assessment	takes	place	only	in	the	context	of	potential	risk.	This	is	especially	important	in	light	of	the	fact	that	most	drug	products	could	not	be	made	without	the	use	of	excipients.
Moreover,	although	excipients	are	not	intended	to	exert	therapeutic	benefits	alone,	they	may	be	necessary	to	achieve	the	full	therapeutic	benefit	of	the	API	(US	FDA,	2005).	Thus,	in	situations	where	the	risk	cannot	be	adequately	characterized	prior	to	use	in	pediatric
patients	and	use	of	the	excipient	cannot	be	bypassed,	but	the	therapeutic	benefit	of	the	active	moiety	is	sufficient,	it	may	be	appropriate	to	proceed	carefully	and	assess	safety	in	the	clinical	setting.
• During	risk	assessment	it	is	important	to	remember	who	tolerates	the	risk.	The	risk	is	not	shared	equally	among	a	number	of	groups:	regulators;	manufacturers;	clinicians;	families	–	parents	and	children;	society.	Ideally,	groups	that	will	suffer	from	the	consequences	of
adverse	events	should	inform	the	risk	assessment.	Thus,	patient	and	caregiver	involvement	in	these	assessments	is	important.
These	perspectives	shared	by	the	Panel	provided	a	base	from	which	participants	engaged	in	breakout	sessions	to	discuss	key	questions	regarding	risk	assessment	paradigms	for	new/novel	excipients	and	those	excipients	with
some	use	history.	Specific	questions	concerned	information	needs,	resources	for	potential	data/information-sharing	platforms,	and	elements	for	a	common	template	or	approach.	The	ensuing	recommendations	for	the	development	of	a
risk-based,	standardized	approach	to	safety	assessment	of	excipients	for	pediatric	use	are	summarized	below.
2	Key	considerations	and	recommendations
2.1	Explicitly	justify	the	need	for	the	excipient(s)
.The	 cross-functional	 exchanges	 at	 the	 workshop	 were	 particularly	 illuminating	 of	 gaps	 in	 understanding	 across	 stakeholders	 involved	 in	 developing	 or	 approving	 excipients	 in	 pediatric	 formulations.	 For	 example,	 non-
formulator	stakeholders	were	sometimes	unclear	as	 to	 the	real	need	 for	such	excipient(s)	with	regard	 to	addressing	specific	 requisites	 for	acceptable	pediatric	 formulations	 (palatability,	ease	of	swallowing,	ability	 to	dose	 titrate,
alternative	dosage	forms).	While	the	potential	use	of	alternative	excipients	should	always	be	considered	if	there	are	limited	or	inadequate	safety	data	for	a	proposed	excipient,	innovations	in	the	usage	of	existing/known	excipients	or	in
the	development	of	novel	excipients	are	often	needed	to	enable	patients	to	benefit	from	these	advancements.	Formulators	need	to	provide	insight	as	to	special	considerations	regarding	the	need	for	and	use	of	specific	excipients	in
pediatric	formulations	(especially	with	regard	to	special	needs	for	younger	age	groups).
2.2	Start	planning	for	pediatric	formulation	development	early
.Formulation	 development	 starts	 well	 in	 advance	 of	 the	 initiation	 of	 pediatric	 studies	 in	 order	 to	 assure	 the	 formulation	 has	 the	 desired	 dose	 flexibility,	 biopharmaceutics,	 stability	 (both	 chemical	 and	 physical),	 and
manufacturing	robustness.	Formulations	are	developed	for	a	defined	target	population(s),	and	delivery	options	are,	by	definition,	age	appropriate.	For	example,	a	solution	or	suspension	formulation	may	be	suitable	for	a	neonate	or
child	under	2	years	of	age	but	not	ideal	for	an	older	child.	Likewise,	due	to	developmental	changes	in	metabolism	and	physiology,	safety	considerations	for	excipients	are	also	age	appropriate.
Formulating	 all	 APIs	 for	 possible	 use	 in	 neonates	 could	 be	 quite	 restrictive	 and	 highly	 impractical.	 Likewise,	 assuming	 all	 pediatric	 populations	 can	 utilize	 the	 adult	 dosage	 form	 ignores	 the	 complexity	 of	 physiological
development	and	enzymatic	ontogeny.	Constructing	the	Paediatric	Investigative	Plan	(PIP)	and	the	Pediatric	Safety	Plan	(PSP)	to	target	age	groups	most	likely	to	benefit	from	study	is	key	to	developing	the	most	relevant	formulation.
Shifts	 in	the	target	population	 later	 in	development,	either	desired	by	the	sponsor	or	requested	by	regulators,	could	have	serious	results	 for	patients,	as	studies	are	conducted	 in	sick	children	and	ethical	considerations	constrain
lengthy	development	timelines	to	include	multiple	formulation	changes.
Any	need	for	additional	nonclinical	studies	with	the	excipient	could	add	significantly	to	the	development	timelines.	Nonetheless,	if	there	are	information	gaps,	these	studies	are	conducted	to	inform	risks	of	excipients	in	advance
of	utilization	in	pediatric	populations.
2.3	Leverage	and	share	existing	data
.Discussions	during	the	breakout	session	helped	participants	to	assess	the	importance	of	developing	a	scientifically	risk-based	framework	in	which	input	from	in	silico,	high-throughput	screening	and	conventional	toxicity	data
can	form	the	basis	of	an	integrated	evaluation	strategy	for	excipients	risk	assessment.	The	use	of	existing	resources	and	barriers	to	sharing	relevant	information	within	the	industry	was	recognized.	The	need	to	integrate	the	existing
safety	and	toxicity	information	of	excipients	from	disparate	resources	under	one	umbrella	was	recognized	by	European	Paediatric	Formulations	Initiative	(EuPFI)	and	drove	the	collaborative	development	of	the	Safety	and	Toxicity	of
Excipients	for	Paediatrics	(STEP)	database	with	the	USPFI.	The	database	is	a	publicly	accessible	evidence	base	of	safety	and	toxicity	information	of	excipients	for	the	pharmaceutical	industry,	academics,	pharmacists,	clinicians	and
regulators	to	help	make	informed	decisions	and	thus	expedite	pediatric	drug	development	(Salunke	et	al.,	2012,	2013;	Salunke	and	Tuleu,	2015).	Participants	emphasized	that,	in	addition	to	referring	to	existing	information	sources	(such
as	the	STEP	database),	data	collected	as	part	of	nonclinical	toxicity	reports	from	the	pharmaceutical,	food,	and	cosmetics	industries	could	hopefully	identify	a	broader	set	of	established	excipients	qualified	by	extensive	safety	data	in
animals	and	humans.	However,	 such	data	acquired	during	drug	development	 is	not	 routinely	published	or	shared	 in	public	databases	owing	 to	 the	confidential	nature	of	 the	research	 that	generates	 the	data.	Additionally,	diverse
methods	of	identifying	excipients,	differing	reliability	and	review	of	databases	were	seen	as	some	of	barriers	in	sharing	the	information.	Several	participants	expressed	their	view	on	the	need	to	promote	productive	sharing	of	the	safety
and	 toxicity	 information	of	 excipients	by	encouraging	 industry	 to	publish	 the	non-proprietary	 information	on	 safety	 and	 tolerability	 information	available	on	excipients.	This	would	maximize	 the	use	of	 vast	quantities	of	data	and
knowledge	generated	throughout	the	research	development	and	regulatory	review	and	avoid	redundancies	in	effort,	speed	the	drug	development	process,	and	lead	to	new	science	and	knowledge	on	excipients.
Meeting	the	challenge	of	data	sharing	will	require	an	extensive	and	ongoing	dialog	between	the	toxicology,	risk	assessment	and	other	related	scientific	communities.	Several	suggestions	were	put	forward	by	the	participants	to
effectively	deal	with	 this	 issue.	 In	 the	big	picture,	 the	STEP	database	may	benefit	users	by	 increasing	the	 flow	of	 information.	However,	 further	effort	 is	required	by	the	sponsors	 to	share,	either	voluntarily	or	upon	request,	non-
confidential	in-house	data	in	the	STEP	database,	to	allow	the	users	access	to	a	much	larger	data	pool	and	prevent	the	repetition	of	a	number	of	toxicity	studies.	The	need	for	expansion	of	the	FDA	Inactive	Ingredients	Database	(IID),
originally	intended	as	a	starting	point	only	from	which	to	establish	prior	use	of	an	excipient,	with	regard	to	content	and	access	was	highlighted.	It	may	be	necessary,	therefore,	to	expand	the	IID	beyond	its	current	scope	to	incorporate
additional	information	on	the	context	of	use	of	individual	excipients	(although	expansion	of	the	IID	will	likely	be	constrained	by	issues	surrounding	the	proprietary	nature	of	excipient	use).	The	International	Pharmaceutical	Excipients
Council	(IPEC)-America	is	working	with	FDA	to	improve	FDA	IID	databaseInsert	citation	for	"Pharmtech	2015",	however	the	inclusion	of	pediatric	formulation	information	may	take	several	years	and	entail	more	resources	than	are	currently
available.	Efforts	may	be	needed	to	identify	suitable	way	to	support	the	improvement	of	the	FDA	IID	database.	Other	regulators	may	be	able	to	share	information	subject	to	compliance	with	any	legal	requirements.
The	 value	 in	 creation	 of	 a	monograph	 around	 the	 commonly	 used	 excipients	 in	 pediatric	 products	was	 discussed.	 Such	monographs	 could	 describe	 and	 integrate	 all	 available	 data	 for	 an	 excipient	 –	 chemical	 properties,
exposure,	excipient	ADME,	systemic	effects	in	animals	and	humans	–	and	outline	recommendations/advice	for	practitioners,	pharmacists,	and	regulators	within	various	context-of-use	scenarios.	The	panel	members	suggested	creation
of	vignettes	that	can	illustrate	the	principles	of	choice	and	values	to	work	to	elucidate	these	choices.	However,	the	challenge	associated	with	this	are	the	efforts	and	resources	needed	to	evaluate	the	existing	data	and	developing	the
monographs.	The	European	Study	of	Neonatal	Excipient	Exposure	(ESNEE)	consortium	has	made	some	progress	in	this	direction.
2.4	Address	challenges	associated	with	novel	excipients
Pharmaceutical	companies	 typically	avoid	 the	use	of	new	excipients	due	 to	additional	safety	data	required	 to	 introduce	a	novel	excipient	 to	a	pharmaceutical	product.	The	resources,	 time,	and	 increased	development	risk
associated	with	this	requirement	makes	formulation	scientists	hesitant	to	try	new	excipients,	thus	hindering	innovation.	Academic	researchers	may	not	have	the	GLP	facilities	to	support	extensive	safety	studies.	Participants	recognized
the	value	of	leveraging	data	available	from	the	food	industry,	however,	that	information	does	not	always	address	specific	context-of-use	scenarios	for	pediatric	patients.	Efforts	from	both	pharmaceutical	and	excipients	manufactures	are
needed	to	bridge	the	gaps	and	 identify	 the	best	practices	and	types	of	data	that	are	needed	for	safety	assessment	of	novel	excipients.	For	 instance,	 the	Novel	Excipients	Working	Group	(members	 from	IPEC-Americas	and	the	IQ
Consortium)	and	a	similar	group	formed	within	IPEC-Americas	are	currently	exploring	the	development	of	joint	best	practices	for	nonclinical	safety	(testing	and	specification	requirements)	and	creating	a	process	for	designing	a	well-
defined	nonclinical	data	package	for	novel	excipients	(Challener,	2014).	It	is	the	intention	that	such	proposals	will	be	discussed	with	regulators,	as	well.
2.5	Develop	context-specific	risk:benefit	analyses	for	excipients
Dr.	Turner	proposed	a	systematic,	risk-based,	proportionate,	prospective	approach	for	selected	safety	assessments.	A	systematic,	prospective	approach	would	supplement	surveillance	for	adverse	events	using	standard	methods
to	detect	potential	reactions	to	excipients,	such	as	spontaneous	reports.	The	proposed	risk-based	approach	is	intended	to	be	used	proportionately,	that	is,	only	when	an	excipient	is	likely	to	be	crucial	to	the	success	of	a	formulation	in	a
high	impact	clinical	situation.	The	proposed	approach	is	summarized	in	the	Figure.	The	steps	are	described	using	the	example	of	a	prospectively	planned	assessment	of	parabens	in	products	 intended	for	enteral	administration	to
babies	born	between	24	and	32	weeks	of	gestation.
Step	1:	define	the	scope	of	the	assessment.	This	step	is	critical	to	identify	the	content	of	the	assessment	and	inform	decisions	about	the	deployment	of	resources.	A	multidisciplinary	team	should	decide	which	variables	are
relevant	including	(age/developmental	stage,	disease	state)	and	the	pharmaceutical	program	(route	of	administration,	dosing	paradigm).	An	example	of	a	scope	could	be	“the	enteral	administration	of	parabens	to	babies	born	between
24	and	32	weeks	of	gestation.”
Step	2:	define	the	goals	of	the	safety	assessment	in	light	of	the	scope.	Use	the	scope	to	identify	which	exposures	and	adverse	events	are	relevant.	In	the	parabens	example,	“which	doses	of	parabens	will	avoid	long-and	short-
term	adverse	events	known	from	animal	studies	and	suggested	in	human	studies	(Anderson,	2008).”
Step	3:	synthesize	the	existing	knowledge	starting	with	systematic	search	methods.	Synthesis	may	be	narrative	or	quantitative	(for	example,	by	building	population	PK	models	for	excipients	when	relevant	data	is	available).
Recent	EMA	documents	about	excipient	labelling	are	good	examples	of	evidence	synthesis	(EMA,	2017).
Step	4:	use	the	knowledge	synthesis,	scope	and	goals	of	the	risk	assessment	to	identify	knowledge	gaps.	Then	apply	reasoned	and	proportionate	judgment	to	prioritize	key	knowledge	gaps.	Examples	of	knowledge	gaps	in	the
parabens	example	would	be:
1 How	much	paraben	is	included	in	existing	products/how	widely	are	existing	products	used?
2 How	does	dosage	relate	to	exposure	(taking	account	of	patient	characteristics)?
3 How	does	exposure	relate	to	effects?
Step	5:	develop	a	judicious	plan	to	reduce	key	knowledge	gaps.	The	plan	may	include	nonclinical	studies	(eg,	to	provide	animal	PKPD	data	that	can	be	bridged	with	clinical	dose-exposure	data)	and/or	clinical	work	(eg	PK
studies	or	structured	safety	assessmentNeed	end	parenthesess.	In	the	paraben	example,	studies	could	include:
1 Survey	manufacturers	of	marketed	products
2 Conduct	study	of	excipient	kinetics	in	babies	administered	existing	paraben-containing	products
3 Conduct	PD	studies	in	suitable	models
Step	6:	design	and	conduct	the	appropriate	studies.	In	the	paraben	example,	some	selected	studies	were	done:
1 	Nellis	et	al.	(2016)	Replace	"Nellis	et	al.	(2016)	with	"Nellis	et	al.	(2015)"conducted	a	survey	of	excipient	use	in	Europe	but	found	that	manufacturers	were	reluctant	to	share	excipient	content	of	many	products
2 	Mulla	et	al.	(2015)	conducted	an	excipient	kinetic	study	in	the	target	population	for	methyl	and	propyl	parabens
NB:	not	all	the	planned	studies	were	feasible,	so	that	any	final	assessment	must	make	the	best	use	of	imperfect	information.
Step	7:	synthesize	the	consequent	new	body	of	knowledge,	for	example,	update	PKPD	or	PoP	PK	models,	conduct	a	meta-analysis,	inform	bridging	from	animals	to	humans.	In	the	parabens	example	data	from	Mulla	et	al.	was
referenced	in	the	EMA	reflection	paper	on	parabens	(2015).	In	high-impact	situations,	a	bridging	exercise	could	be	done	between	PKPD	studies	in	animals	and	the	available	PK	data	in	humans	(compare	work	done	with	Vancomycin	in
neonates,	Ramos-Martín	et	al.,	2016)
Step	8:	perform	risk	assessment	in	the	light	of	the	new	body	of	knowledge,	eg,	provide	balanced	recommendations	considering	internal	vs	external	validity	of	the	model	or	data;	consider	clinical	implications;	consider	risk
mitigation	strategies.	The	parabens	example	includes	the	dosages	for	parabens	included	in	the	EMA	reflection	paper	(2015).	Clinical	benefit-risk	assessment	suggests	that	it	is	appropriate	to	continue	using	existing	products	containing
methyl	and	propyl	parabens	in	this	population	Fig.	2.
Interpretation	of	all	the	information	could	result	in	possible	actions	for	excipients	of	concern,	including	termination	(when	the	risk	of	adversity	is	too	high);	the	conduct	of	additional	studies	to	further	understand	potential	risks;
or	the	implementation	of	clinical	monitoring	of	exposure	or	biomarkers	of	safety.
2.5.1	Engage	All	Sall	stakeholders
Decisions	about	benefit	and	risk	tolerance	should	be	determined	by	clinicians,	regulators,	patients,	and	caregivers.	High-impact	safety	assessments	may	be	built	around	meaningful	stakeholder	engagement.	Parents	and	children	can	present	a
Fig.	2	A	systematic,	risk-based	approach	to	the	prospective	safety	assessment	of	excipients	to	be	used	in	pediatric	medicines:	each	step	should	be	adapted	to	the	product	and	target	population.
alt-text:	Fig.	2
distinct	perspective,	especially	for	serious	diseases	with	few	available	options.	The	context-dependence	of	family	tolerance	of	risk	can	be	observed	in	trials	of	novel	therapies.	For	example,	among	children	and	their	families,	the	risk	tolerance	for	gene
therapy	can	be	much	higher	if	the	condition	is	life-threatening	and	otherwise	untreatable	than	for	other	conditions.	Less-dramatically,	a	family’s	tolerance	for	potential	harms	arising	from	an	excipient	in	an	inotrope	may	be	greater	than	for	an	excipient	in
vitamin	drops.
Engaging	patient	advocate	groups	to	help	develop	“archetypes”	for	various	risk:benefit	scenarios	could	be	very	useful	for	drug	developers	and	regulators	by	providing	the	ranges	of	risk	that	can	be	tolerated	by	a	stakeholder	group.
2.6	Engage	Rregulators
For	development	programs	for	specific	drugs,	sponsors	should	consider	early	interaction	in	the	pre-IND	stage	(US)	or	before	PIP	submission	(EU)	to	gain	regulatory	insight	and	alignment	regarding	for	example,	the	appropriate
age	range	of	the	target	population	and	the	use	of	excipients	to	optimize	drug	product	performance	and	efficacy.	Sponsors	should	provide	regulators	with	all	relevant	data	from	prior	studies,	medical	and	toxicology	 literature,	and
available	databases	(i.e.	STEP,	IID,	GRAS,	etc.).	A	collaborative	discussion	can	then	ensue	to	determine	if	additional	data	are	needed	for	assessment	of	excipient	safety.
In	addition	to	the	regular,	drug-specific	meetings,	opportunities	to	engage	in	general	(non-product-specific)	scientific	discussions	should	be	leveraged.	Similarly,	multi-stakeholder	collaborative	efforts	(FDA,	EMA,	PMDA,	Health
Canada	 and	 Australia)	 directed	 at	 jointly	 addressing	 or	 discussing	 a	 formulation	 issue	 in	 a	 non-application-specific	way	 could	 help	 to	 improve	 industry	 and	 regulatory	 confidence	 around	 use	 of	 excipients	 in	 pediatrics.	Monthly
discussion	among	regulators	normally	entails	reviews	of	drug	applications	but	without	any	formulation	discussions.	International	regulatory	groups	such	as	the	Pediatric	Cluster	include	regulatory	scientists	from	FDA,	EMA,	Health
Canada,	PMDA.	Such	groups	may	provide	a	 forum	 for	 rich	discussion	 regarding	use	of	excipients	 in	pediatrics	and	may	potentially	encourage	progress	 towards	harmonized	 requirements.	Finally,	 various	consortia	 (public-private
partnerships)	interested	in	safety	topics	in	drug	development	may	be	leveraged	for	a	more	broadly	informed,	collaborative	analysis	of	excipient	safety.
3	Conclusion
The	development	of	effective	and	safe	formulation	of	drugs	to	treat	pediatric	patients	is	rife	with	complexities	related	to	the	diversity	of	the	populations	(neonate	to	adolescent),	the	need	for	novel	technologies	and	approaches
by	Formulators	to	optimize	efficacy	of	active	ingredients	in	ways	amenable	to	those	patient	populations,	and	the	lack	of	mechanisms	to	effectively	share	data	and	experience	in	the	scientific	community.	Industry	drug	development
teams	need	to	developing	target	product	profiles	as	early	as	possible,	understanding	that	the	dynamics	of	drug	development,	including	unanticipated	(and	potentially,	disparate)	regulatory	requests	for	consideration	of	additional	age
groups,	will	require	some	flexibility	in	approach.	Development	of	archetypes	to	frame	constraints	for	various	patient	populations	could	be	helpful,	keeping	in	mind	that	it	is	the	younger	patient	groups	that	set	the	risk	posture	around
excipients	in	pediatric	formations.	A	collaborative	partnership	with	different	disciplinary	groups	in	regulatory	agencies	(eg,	Chemists/Formulators,	Pharmtox	and	Medical	Reviewers,	and	Pediatric	experts)	at	early	pre-IND	stages	(US)
or	 prior	 to	 PIP	 submission	 (EU)	 should	 be	 considered.	However,	 the	 lack	 of	 harmonization	 in	 approach	 (for	 example,	 on	 the	most	 appropriate	 age	 group(s)	 for	 a	 given	 therapeutic)	 between	 regulatory	 agencies	 presents	 further
challenges.	 By	 enabling	 practical	 and	meaningful	 discussion	 between	 scientists	 representing	 the	 diversity	 of	 involved	 disciplines	 (formulators,	 nonclinical	 scientists,	 clinicians,	 and	 regulators)	 and	 geographies	 (eg,	 US,	 EU),	 the
Excipients	Safety	workshop	session	was	successful	in	providing	specific	and	key	recommendations	for	defining	paths	forward.	Leveraging	orthogonal	sources	of	data	(eg.	food	industry,	agro	science),	collaborative	data	sharing,	and
increased	awareness	of	the	existing	sources	such	as	the	STEP	database	will	be	important	to	address	the	gap	in	excipients	knowledge	needed	for	risk	assessment.	The	importance	of	defining	risk-based	approaches	to	safety	assessments
for	 excipients	 vital	 to	 pediatric	 formulations	was	 emphasized,	 as	was	 the	 need	 for	meaningful	 stakeholder	 (eg,	 patient,	 caregiver)	 engagement.	 As	 development	 of	 pediatric	 dosage	 forms	 progresses,	 additional	 experiences	with
excipients	will	further	an	evolving	and	shared	landscape	for	future	pediatric	development.
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